Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Total Current Liabilities: 2021-2025

Historic Total Current Liabilities for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $91.3 million.

  • Krystal Biotech's Total Current Liabilities rose 1.94% to $91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.3 million, marking a year-over-year increase of 1.94%. This contributed to the annual value of $102.0 million for FY2024, which is 208.20% up from last year.
  • As of Q3 2025, Krystal Biotech's Total Current Liabilities stood at $91.3 million, which was up 5.03% from $86.9 million recorded in Q2 2025.
  • Krystal Biotech's 5-year Total Current Liabilities high stood at $102.0 million for Q4 2024, and its period low was $9.1 million during Q1 2021.
  • Its 3-year average for Total Current Liabilities is $62.6 million, with a median of $71.9 million in 2024.
  • Per our database at Business Quant, Krystal Biotech's Total Current Liabilities surged by 560.95% in 2022 and then plummeted by 41.96% in 2023.
  • Krystal Biotech's Total Current Liabilities (Quarterly) stood at $25.7 million in 2021, then increased by 12.09% to $28.8 million in 2022, then climbed by 14.72% to $33.1 million in 2023, then spiked by 208.20% to $102.0 million in 2024, then climbed by 1.94% to $91.3 million in 2025.
  • Its Total Current Liabilities was $91.3 million in Q3 2025, compared to $86.9 million in Q2 2025 and $79.5 million in Q1 2025.